EEElardus Erasmus

Elardus Erasmus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elardus Erasmus has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Carien Leandri Van der Berg

    Human Metabolomics, North-West University (Potchefstroom Campus), Potchefstroom, 2531, South Africa

    5 shared publications
  • Francois Hendrikus van der Westhuizen

    Mitochondria Research Group, Biomedical and Molecular Metabolism Research (BioMMet), North-West University, Potchefstroom, South Africa

    5 shared publications
  • Gerda Venter

    Biomedical and Molecular Metabolism Research, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom, South Africa; Department of Biochemistry, Faculty of Natural and Agricultural Sciences, North-West University, Cnr Albert Luthuli and University Drive, Mmabatho, South Africa

    5 shared publications
  • B. Chris Vorster

    Centre for Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-West University (Potchefstroom Campus), Private Bag X6001, Potchefstroom, South Africa

    2 shared publications
  • Carolus J. Reinecke

    Centre for Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-West University (Potchefstroom Campus), Private Bag X6001, Potchefstroom, South Africa

    2 shared publications
  • Francois E. Steffens

    Department of Consumer Science, University of Pretoria, Pretoria, South Africa

    2 shared publications

Latest Publications

  • Open Access

    Comparative redox and sulfur-metabolic effects of methylsulfonylmethane, N-acetylcysteine, and vitamin C during acute inflammatory stress

    by Heidi N. du Preez, Sooraj Baijnath, Carien Leandri Van der Berg, Elardus Erasmus, Ilse Du Preez, Hendrick G. Kruger

    Sulfur metabolism is a critical yet underexplored regulator of redox balance, inflammatory signaling, and methylation capacity. Methylsulfonylmethane (MSM) has been proposed to influence these pathways, but its metabolic effects remain poorly defined relative to classical antioxidants. In this study, MSM was compared with N-acetylcysteine (NAC) and vitamin C in a rat model of lipopolysaccharide-induced inflammatory stress, integrating targeted sulfur and one-carbon metabolomics with oxidative, inflammatory, endothelial, and mitochondrial biomarkers.At 18 h post-challenge, MSM produced a distinct sulfur-flux signature characterized by reduced cysteine-S-sulfate and homocysteine without accumulation of oxidized sulfur derivatives, decreased S-adenosylhomocysteine, and an increased S-adenosylmethionine/S-adenosylhomocysteine ratio, consistent with attenuation of sulfite stress and stabilization of methylation balance. In contrast, NAC and vitamin C modulated cysteine and S-adenosylmethionine, but were associated with higher oxidized sulfur species, reflecting direct thiol and electron-donor buffering. Systemic inorganic sulfate levels remained unchanged across groups, indicating tight whole-body regulation; however, MSM-specific upstream shifts suggest enhanced capacity for tissue-level sulfation.Classical markers of endothelial activation and glycocalyx shedding did not differ between groups, likely reflecting the timing of sampling relative to acute shedding kinetics. All interventions reduced urinary free carnitine, consistent with preserved mitochondrial β-oxidation. MSM was associated with modest, coordinated, non-suppressive cytokine changes indicative of adaptive immunomodulation.Collectively, these findings identify MSM as a sulfation-directed metabolic regulator that stabilizes sulfur and methylation pathways under inflammatory stress, distinguishing it mechanistically from conventional antioxidants and expanding redox biology to include sulfur trafficking and sulfation-dependent regulation with relevance to inflammatory and barrier-related disease processes.

  • Open Access

    Hair cortisol/cortisone in combined oral contraceptive users: An exploratory analysis

    by Daniela Seany Dorfling, Gerda Venter, Elardus Erasmus

  • Open Access

    Oral contraceptives containing ethinyl estradiol and drospirenone increase hydroxylation and methylation of endogenous estrogen but not genotoxic estrogen DNA-adduct formation

    by Gerda Venter, Carien L. van der Berg, Tarien Jacobs, Francois H. van der Westhuizen, Elardus Erasmus

    Combined oral contraceptives (COCs) are commonly prescribed for the prevention of pregnancy, as well as numerous other non-contraceptive health reasons. COCs act by suppressing the natural hormonal fluctuations of the menstrual cycle that result in ovulation. No studies have investigated the effects of COC use on endogenous estrogen biotransformation and the production of estrogen metabolites. This is important since imbalances in hormone biotransformation (e.g., inefficient methylation by catechol O-methyltransferases; COMT) are implicated in the initiation of breast cancer through the generation of genotoxic metabolites (i.e., estrogen quinones) and reactive oxygen species (ROS), and the depletion of vital antioxidants and metabolic cofactors. Here, we quantified the urinary levels of various estrogen precursors and metabolites in healthy young women who were using COCs containing drospirenone (DRSP) and ethinyl estradiol (EE) (n = 24) and controls (n = 25) via liquid chromatography–tandem mass spectrometry (LC‒MS/MS). In addition, we analysed several circulatory intermediates of the methylation cycle that are linked to the methylation of catechol estrogens via LC‒MS/MS. We found that free urinary estradiol (E2) and estrone (E1) were significantly lower, while 2-methoxyestrone (2-MeOE1) levels were significantly higher in COC users. Excretion of some metabolites including 16-hydroxylation pathway metabolites, glutathione conjugates, and DNA-adducts were also lower in COC users, although total hormone and metabolite excretion levels were not significantly different. Estrone metabolite ratios were higher in COC users, including 2&4-MeOE1:E1, 2&4-OHE1:E1, E1-3-sulphate: E1, and E1-3-glucuronide: E1. There was a positive correlation between 2-hydroxyestrogen and 2-methoxyestrogen levels in controls but not in COC users. In addition, the serum betaine and dimethylglycine (DMG) levels, as well as the betaine: choline ratio, were reduced in COC users, whereas the levels of choline and serine and the DMG: betaine ratio were significantly increased. DMG levels positively correlated with methoxyestrogens and methoxyestrogen: hydroxyestrogen ratios in COC users, while S-adenosylmethionine (SAM) negatively correlated with 2-MeOE2. Our data suggests that the use of EE/DRSP increases the flux of endogenous hormones into the hormone biotransformation pathway, resulting in increased conversion of estrogens (especially E1) into conjugated, catechol, and methylated estrogens but that the latter is limited by methyl-group donor availability. Interestingly, the increased oxidation of estrogens in COC users does not result in increased DNA-adduct formation.

  • Open Access

    Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol

    by Gerda Venter, Carien L. van der Berg, Francois H. van der Westhuizen, Elardus Erasmus

    Combined oral contraceptive (COC) use has been associated with various adverse effects. Formulations containing drospirenone (DRSP) and ethinyl estradiol (EE) are generally regarded as milder COCs. Whether long term use of these pills indeed has a low health risk remains questionable. COC use may affect the biotransformation balance by increasing the toxic load or by interfering with the pharmacokinetics of other drugs. This may negatively impact overall health via the production of toxic biotransformation metabolites and induction of oxidative stress. Although individual enzymes involved in biotransformation are known to be regulated by COCs, the effect of COC use on the overall liver biotransformation efficiency has not been reported. Here, we evaluated the general subjective health status and overall liver biotransformation efficiency of healthy young women who were either long term chronic users of COCs containing DRSP/EE, or who were not using any hormonal products. COC users suffered from moderate to severe fatigue and reported more health-related symptoms. Furthermore, phase I (CYP1A2) activity was reduced whereas phase II conjugation reactions (glucuronide conjugation and glycine conjugation) were increased in COC users. Finally, serum peroxide levels were markedly elevated and antioxidant capacity of plasma was reduced in COC users. COCs containing DRSP/EE may, therefore, adversely affect health status and disturb the balance between phase I and II biotransformation reactions. These effects may be mediated by oxidative stress.


  • Open Access

    Data on the optimisation of a solid phase extraction method for fractionating estrogen metabolites from small urine volumes

    by Carien L. van der Berg, Gerda Venter, Francois H. van der Westhuizen, Elardus Erasmus


  • A laboratory approach for characterizing chronic fatigue: what does metabolomics tell us?

    by Elardus Erasmus, Shayne Mason, Mari van Reenen, Francois E. Steffens, B. Chris Vorster, Carolus J. Reinecke

    Manifestations of fatigue range from chronic fatigue up to a severe syndrome and myalgic encephalomyelitis. Fatigue grossly affects the functional status and quality of life of affected individuals, prompting the World Health Organization to recognize it as a chronic non-communicable condition.


  • Open Access

    Biotransformation profiles from a cohort of chronic fatigue women in response to a hepatic detoxification challenge

    by Elardus Erasmus, Francois E. Steffens, Mari van Reenen, B. Chris Vorster, Carolus J. Reinecke

    Chronic fatigue, in its various manifestations, frequently co-occur with pain, sleep disturbances and depression and is a non-communicable condition which is rapidly becoming endemic worldwide. However, it is handicapped by a lack of objective definitions and diagnostic measures. This has prompted the World Health Organization to develop an international instrument whose intended purpose is to improve quality of life (QOL), with energy and fatigue as one domain of focus. To complement this objective, the interface between detoxification, the exposome, and xenobiotic-sensing by nuclear receptors that mediate induction of biotransformation-linked genes, is stimulating renewed attention to a rational development of strategies to identify the metabolic profiles in complex multifactorial conditions like fatigue. Here we present results from a seven-year study of a cohort of 576 female patients suffering from low to high levels of chronic fatigue, in which phase I and phase II biotransformation was assessed. The biotransformation profiles used were based on hepatic detoxification challenge tests through oral caffeine, acetaminophen and acetylsalicylic acid ingestion coupled with oxidative stress analyses. The interventions indicated normal phase I but increased phase II glucuronidation and glycination conjugation. Complementarity was indicated between a fatigue scale, medical symptoms and associated energy-related parameters by application of Chi-square Automatic Interaction Detector (CHAID) analysis. The presented study provides a cluster of data from which we propose that multidisciplinary inputs from the combination of a fatigue scale, medical symptoms and biotransformation profiles provide the rationale for the development of a comprehensive laboratory instrument for improved diagnostics and personalized interventions in patients with chronic fatigue with a view to improving their QOL.


  • Open Access

    Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome

    by Elizna M. Schoeman, Francois H. Van Der Westhuizen, Elardus Erasmus, Etresia van Dyk, Charlotte V. Y. Knowles, Shereen Al-Ali, Wan-Fai Ng, Robert W. Taylor, Julia L. Newton, Joanna L. Elson

    Chronic Fatigue Syndrome (CFS) is a prevalent debilitating condition that affects approximately 250,000 people in the UK. There is growing interest in the role of mitochondrial function and mitochondrial DNA (mtDNA) variation in CFS. It is now known that fatigue is common and often severe in patients with mitochondrial disease irrespective of their age, gender or mtDNA genotype. More recently, it has been suggested that some CFS patients harbour clinically proven mtDNA mutations. MtDNA sequencing of 93 CFS patients from the United Kingdom (UK) and South Africa (RSA) was performed using an Ion Torrent Personal Genome Machine. The sequence data was examined for any evidence of clinically proven mutations, currently; more than 200 clinically proven mtDNA mutations point mutations have been identified. We report the complete mtDNA sequence of 93 CFS patients from the UK and RSA, without finding evidence of clinically proven mtDNA mutations. This finding demonstrates that clinically proven mtDNA mutations are not a common element in the aetiology of disease in CFS patients. That is patients having a clinically proven mtDNA mutation and subsequently being misdiagnosed with CFS are likely to be rare. The work supports the assertion that CFS should not be considered to fall within the spectrum of mtDNA disease. However, the current study cannot exclude a role for nuclear genes with a mitochondrial function, nor a role of mtDNA population variants in susceptibility to disease. This study highlights the need for more to be done to understand the pathophysiology of CFS.


  • The Use ofp‐Aminobenzoic Acid as a Probe Substance for the Targeted Profiling of Glycine Conjugation

    by Carla Nortje, Rencia van der Sluis, Alberdina Aike van Dijk, Elardus Erasmus

    Glycine conjugation facilitates the metabolism of toxic aromatic acids, capable of disrupting mitochondrial integrity. Owing to the high exposure to toxic substrates, characterization of individual glycine conjugation capacity, and its regulatory factors has become increasingly important. Aspirin and benzoate have been employed for this purpose; however, adverse reactions, aspirin intolerance, and Reye's syndrome in children are substantial drawbacks. The goal of this study was to investigatep‐aminobenzoic acid (PABA) as an alternative glycine conjugation probe. Ten human volunteers participated in a PABA challenge test, andp‐aminohippuric acid (PAHA),p‐acetamidobenzoic acid, andp‐acetamidohippuric acid were quantified in urine. The glycineN‐acyltransferase gene of the volunteers was also screened for two polymorphisms associated with normal and increased enzyme activity. All of the individuals were homozygous for increased enzyme activity, but excretion of PAHA varied significantly (16–56%, hippurate ratio). The intricacies of PABA metabolism revealed possible limiting factors and the potential of PABA as an indicator of Phase 0 biotransformation.